GAINESVILLE, Fla. — October 7, 2025 — Leads & Copy — NeXtGen Biologics has announced the issuance of its third U.S. patent, US12311079, granted on May 27, 2025. This patent is part of a suite of U.S. and foreign patents related to extracellular matrix components derived from axolotls, a highly regenerative, non-mammalian species.
The new patent covers a tissue culture system, providing patent coverage for two conditioned media and ECM, along with methods for using these products. CEO Jonelle Toothman noted that this patent affirms the significance of their previous patents and the company’s dedication to transforming patient care. NeXtGen’s technology is establishing new standards in wound care, through its FDA-cleared NeoMatriX® Wound MatriX, and regenerative medicine.
NeXtGen’s portfolio includes 3 U.S. patents, 1 pending U.S. patent, and 8 foreign patents, leading to clinical applications. The company states they are the only commercially operating enterprise in the world leveraging axolotl-derived technology in clinical applications.
NeXtGen Biologics, Inc., based in Alachua, FL, is focused on developing advanced solutions for challenges in wound care, trauma, plastic surgery, cardiovascular disease, neurosurgery, orthopedics, and ophthalmology, leveraging its expertise in medical devices and breakthrough tissue technologies.
Contact: Jonelle Toothman, 904-599-3264, jltoothman@nextgenbiologics.com
Source: NeXtGen Biologics, Inc.
